I think that's an inaccurate statement. BMSN seems to put news out whenever they have news to release. Every 2 months is quite a bit off when you actually look at it. Over the last 9 months there have been 10 PRs which equals out to just over one PR per month. Here are the dates from the most recent PRs:

7/31/13
8/8/13
8/16/13
9/17/13
9/25/13
9/26/13
10/9/13
10/31/13
12/11/13
3/6/14

The reason for the 31st of March "deadline" comes from Regen BioPharma's S-1/A which states:

"Based on these assumptions, during the three months ending March 31, 2014 the Company anticipates completion of all actions required to be undertaken with regards to addressing comments made by the US Food and Drug Administration with regards to the IND filed by the Company for HemaXellerate I. The Company also anticipates commencement of the Phase I clinical trial for HemaXellerate I anticipated to begin July 2014. The Company intends, upon satisfaction of all comments, to seek Orphan Drug Designation under the Orphan Drug Act of 1983 from the US Food and Drug Administration for HemaXellerate I. During the three months ended March 31, 2014 the Company also anticipates completion of preclinical testing with regards to dCellVax as well as submission of an IND to the FDA with regards to dCellVax."


http://www.sec.gov/Archives/edgar/data/1589150/000155479514000141/regen22714s1a.htm

I remember seeing that on the website quite a while back as I added it to the intro page here on iHub months ago.

HOWEVER, I don't recall ever seeing a regulatory filings tab and it has filings listed on it from 2014 so it must be fairly new.

http://regenbiopharma.com/regulatory.html

HemaXellerate I, while its INITIAL indication will be for the treatment of aplastic anemia, is also intended to be used for other conditions relating to the failure of blood production by bone marrow. The company clearly intends on using HemaXellerate I for the treatment of other conditions which = more potential revenues.

This is from their 7/31/13 PR:

3. Demonstrating proof of concept in this patient population will not only provide a potential Orphan Drug designation, but also will allow entry into other conditions associated with failure of the bone marrow to produce blood. This market is substantial in size and currently is addressed by biological drugs such as Neupogen®, Neulasta®, Leukine® and Revolade®.

http://finance.yahoo.com/news/bio-matrix-scientific-group-provides-183607269.html

No problem Dr. V. Here's links to the published studies supporting all of our treatments for you or anyone who hasn't seen them yet:

dCellVax (for breast cancer) - February 2013
http://www.ncbi.nlm.nih.gov/pubmed/22870862

dCellVax (for melanoma) - March 2014
http://www.ncbi.nlm.nih.gov/pubmed/24509175

HemaXellerate - November 2012
http://www.ncbi.nlm.nih.gov/pubmed/23171397

Nicely worded! One thing to mention also, the study that was just published in March 2014 that I previously posted shows dCellVax is effective for the treatment of Melanoma as well!

So they may have one treatment that can knock out breast cancer and skin cancer! That equals mega-bucks. This on-top of all the other stuff you just spoke about.

Did you click the link I provided to the OTC Market Place's website? It lists BMSN as OTCQB. I'm pretty sure they would be the leading authority on the issue.

It does directly apply to BMSN because we are OTCQB, not Pink sheets.

http://www.otcmarkets.com/stock/BMSN/quote

No, we are not Pink, we are OTCQB

http://www.otcmarkets.com/stock/BMSN/quote

No dilution for over 2months as per the transfer agent.

The pirate isn't a moderator...look at the list of mods at the top of the page...each mod gets (1) sticky...so that should narrow down your investigation

I believe that you would still retain your dividend based on the fact that the pay date was the 25th. I am not an expert in dividends however and this is a unique dividend in and of itself.

For those with Scottrade Accounts, I just spoke to a representative who advised that according to their corporate offices, they are expecting to receive a dividend for the Regen BioPharma shares this afternoon and expect to post them to our accounts this evening. He also confirmed the rate of distribution as what we were expecting.

Also, the reason for the delay according to him, was the fact that Scottrade is not a market maker and has to await payment of the shares from the market makers as they receive the shares first and distribute them out (kind of a trickle down effect).

Strange. I'm not getting a hit this time.

What search did you do? I'm not seeing it this time.

Thanks for posting so now all of the doubters can shut up (about the dividend not being real at least). Now they can move on to some other ludicrous claim! Haha!

???People obviously did "scarf" more shares up at .002 and .003; hence the rise up to .009 to begin with. Hope that helps with your befuddled-ness.

Yeah, we've determined it is a bogus article and has no merit.

The PoPo Wednesday, 03/26/14 11:37:39 AM
Re: TaylaBell post# 122990
Post # of 123044

The article is completely erroneous. The company that PRed about their CEO attending a conference is BioTime not Bio-Matrix. What a joke of a blogger.

http://online.wsj.com/article/PR-CO-20140325-906769.html

The PoPo Wednesday, 03/26/14 11:45:06 AM
Re: SKIPPERANDGILLIGAN post# 123017
Post # of 123046

No, it's just erroneous. He is the CEO of Bio-Time, not Bio-Matrix. I just posted the link to the recent PR by Bio-Time that announced the info that the article was claiming was about Bio-Matrix.

Also, the conference that guy is attending is called the Annual Regen Med Investor Day and that's also partly where the confusion came from as well if I had to guess.

http://online.wsj.com/article/PR-CO-20140325-906769.html

http://alliancerm.org/event/regen-med-investor-day

I never said you were wrong on that particular issue because I didn't call the T/A myself to confirm one way or the other. But I'll give credit where credit is due, you were right on that one.

No, it's just erroneous. He is the CEO of Bio-Time, not Bio-Matrix. I just posted the link to the recent PR by Bio-Time that announced the info that the article was claiming was about Bio-Matrix.

Also, the conference that guy is attending is called the Annual Regen Med Investor Day and that's also partly where the confusion came from as well if I had to guess.

http://online.wsj.com/article/PR-CO-20140325-906769.html

http://alliancerm.org/event/regen-med-investor-day

The article is completely erroneous. The company that PRed about their CEO attending a conference is BioTime not Bio-Matrix. What a joke of a blogger.

http://online.wsj.com/article/PR-CO-20140325-906769.html

Who the hell is West?

Ok, we understand your sentiment, although it has apparently completely changed from your prior repetitive claims that this was a "scam", however, you need to stop spamming the board with a thousand posts.

BMSN chart still bouncing off of the 20MA.



...and thanks ctvette, I don't have premium membership or the ability to send private messages but I appreciate your thoughts and would love to hear what you learn.

I don't have the picture. Do you have a picture of this houseboat? Did YOU even see the alleged "houseboat office" yourself? I actually saw the pictures myself of Koos and the office. If you're really in that much doubt about whether this company has an office at all, I don't think you should be invested in this company (if you really are).

It was sometime in the latter part of last year around August or so. I don't think the poster put a pic up in the forum but made it their profile pic for a while. It's definitely a real building and the real Koos!

We already had someone on this board who had taken pictures with Koos and at the outside of their office with the company name on it. FYI to those who may not have been here then. It IS a real place LOL

Well of course the more data they have, the more likely it is to be approved. That's the case with anything. You just responded a moment ago to another poster's question about whether or not the IND had to be approved to apply for orphan status and you told them incorrectly that it did. I was just correcting your mistake.

This is straight from the FDA's policy:

§316.20 Content and format of a request for orphan-drug designation.

(a) A sponsor that submits a request for orphan-drug designation of a drug for a specified rare disease or condition shall submit each request in the form and containing the information required in paragraph (b) of this section. A sponsor may request orphan-drug designation of a previously unapproved drug, or of a new use for an already marketed drug.

§316.23 Timing of requests for orphan-drug designation; designation of already approved drugs.

(a) A sponsor may request orphan-drug designation at any time in its drug development process prior to the time that sponsor submits a marketing application for the drug for the same rare disease or condition.

http://www.ecfr.gov/cgi-bin/text-idx?c=ecfr&SID=238362420de6b80c19b2a9c44b73a843&rgn=div6&view=text&node=21:5.0.1.1.6.3&idno=21

It is not possible for any of us to know for certain whether they have filed for orphan drug status yet or not. According to the FDA protocol you can file for orphan drug status at any point within the filing (including prior to IND approval). Therefore it would make the most sense to file for it as soon as possible; I personally believe that they have filed for it already.

§316.20 Content and format of a request for orphan-drug designation.

(a) A sponsor that submits a request for orphan-drug designation of a drug for a specified rare disease or condition shall submit each request in the form and containing the information required in paragraph (b) of this section. A sponsor may request orphan-drug designation of a previously unapproved drug, or of a new use for an already marketed drug.

§316.23 Timing of requests for orphan-drug designation; designation of already approved drugs.

(a) A sponsor may request orphan-drug designation at any time in its drug development process prior to the time that sponsor submits a marketing application for the drug for the same rare disease or condition.

http://www.ecfr.gov/cgi-bin/text-idx?c=ecfr&SID=238362420de6b80c19b2a9c44b73a843&rgn=div6&view=text&node=21:5.0.1.1.6.3&idno=21

That's incorrect. You do not need IND approval to begin trials in order to file for orphan drug status. Per the FDA regulations you can apply for orphan drug status at any point in the process prior to market approval.

Thanks! Also, this is directly from the Prospectus for Regen BioPharma just filed March 18, 2014:

"The Company’s current intention is to initiate and complete Phase I and Phase II clinical trials with regard to HemaXellerate I and, upon successful completion of a Phase II clinical trial, seek to license the product out to one or more licensees.

Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a previously unapproved drug or biologic intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a seven year period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for that time period. The sponsor of the product would also be entitled to a United States federal tax credit equal to 50% of clinical investigation expenses as well as exemptions from certain fees."


http://www.sec.gov/Archives/edgar/data/1589150/000155479514000214/regen31714424b3.htm

Yes, selling would typically be a one-time payment based on the value of the technology at the time the agreement was made. Licensing out would generate long-term profits as the treatment (hopefully) successfully progressed through the remaining phases of clinical trials and hopefully was eventually marketed. The reason they believe this model is better than other models is because we are able to take chances on multiple therapies without extensive R&D costs and without advancing to the most costly phases of clinical trials.

I personally believe we would license out HemaXellerate I because we are seeking orphan drug status with its indication for aplastic anemia. If you read closely you will see in many of the filings it states that this is just the FIRST indication for HemaXellerate I. Getting orphan drug status on the first indication is key to being able to rapidly advance its progression through trials as well as getting $$$ breaks from the government and 7-year exclusivity rights to marketing if it makes it that far.

For an example of how licensing out technologies can be profitable just look at our current partner, Benitec. We just licensed their ddRNAi treatment last August. Here is our contract with them:

http://www.sec.gov/Archives/edgar/data/1589150/000155479513000605/reg1009forms1ex10_12.htm

Sure. We plan on getting these therapies through Phase I or Phase II Clinical Trials ourselves. After that we plan on selling these therapies or licensing them out to other companies.

The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. The approach is a highly focused analysis of issued patents in regenerative medicine, identification and acquisition of undervalued assets that have demonstrated proof of concept, and forming companies around these assets.


Regen BioPharma has assessed over 20,000 stem cell related issued patents, narrowed down to 2000 patents with commercial applicability, and further identified 30 patents available for licensing. The company seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies.

http://www.regenbiopharma.com/business-model.html

http://www.regenbiopharma.com/our-approach.html

"Dr. Ichim is a cancer specialist turned stem cell genius, and his unfulfilled dream is to create a cancer “vaccine” powered by stem cells that can work around all the problems still facing most researchers. However, he stopped along the way to lead MediStem to the most advanced adult stem cells (or Repair Stem Cells) in practical use today."


This is from an article written in 2009. Now that Dr. Ichim has finished his pit stop with Medistem, he can get back to fulfilling his DREAM with Regen BioPharma!

http://www.repairstemcells.org/Resources/Stem-Cell-Articles/Don-Margolis-Visits-The-Stem-Cell-Company-Called-M.aspx

Updated BMSN/Regen BioPharma Timeline for IND Approval According to S-1/A and PRs

9/24 - Began additional efficacy tests (Estimated to last 3 months according to S-1/A)

(This is the testing the PR on 12/11 was announcing the completion of)

12/11 - Additional safety tests were already underway (Estimated to last 2 months according to S-1/A)

(This is the testing Dr. Min stated was already under way on the 12/11 PR)

2/11 - Safety tests should be completed

The S-1/A states that the company expects approval by March 31, 2014 and the initiation of Phase I Trials to begin in July 2014.

Also, the company anticipates filing of the dCellVax IND by March 31, 2014.

Yup! I agree, the 20MA is holding up nicely just like last year!

Also, I don't have private messaging ability on here, but in regard to your question....not many but you will pick up on it.

I post facts with substantial proof and CREDIBLE sources to back it all up. You post copy and paste information from someone else's posts and then argue with people when they try to show you that something you previously said was erroneous.

You said a moment ago that dividends are less than 25% of the parent company which made it sound as if you were claiming that ALL dividends are less than 25% of the parent company. Which clearly is not the case.

Another key word that many people are missing from the SEC site in regard to special dividend ex-dates is the word USUALLY:

"If you sell your stock before the ex-dividend date, you also are selling away your right to the stock dividend. Your sale includes an obligation to deliver any shares acquired as a result of the dividend to the buyer of your shares, since the seller will receive an I.O.U. or "due bill" from his or her broker for the additional shares. Thus, it is important to remember that the day you can sell your shares without being obligated to deliver the additional shares is not the first business day after the record date, but usually is the first business day after the stock dividend is paid."

https://www.sec.gov/answers/dividen.htm

I guess it was! You slapped VNDM back 10 ticks if that was you lol